Jump to content

Teva Pharmaceuticals

From Wikipedia, the free encyclopedia

Teva Pharmaceutical Industries Ltd.
Company typePublic
IndustryPharmaceutical
Founded1901;123 years ago(1901)
Founders
Headquarters
Tel Aviv
,
Israel[1]
Key people
RevenueIncreaseUS$15.8 billion(2023)[2]
IncreaseUS$433 million(2023)[2]
DecreaseUS$−559 million(2023)[2]
Total assetsDecreaseUS$43.5 billion(2023)[2]
Total equityDecreaseUS$8.13 billion(2023)[2]
Number of employees
37,851 (2023)[2]
Websitetevapharm
teva.co.il
Günther Friedländer,founder of Teva Pharmaceutical Industries in Jerusalem

Teva Pharmaceutical Industries Ltd.(also known asTeva Pharmaceuticals) is an Israeli multinationalpharmaceuticalcompany. Teva specializes primarily ingeneric drugs,but other business interests include branded-drugs,active pharmaceutical ingredients(API's) and, to a lesser extent, contract manufacturing services and an out-licensing platform.[3]

Teva's primary branded products include Austedo (deutetrabenazine) which is used for the treatment ofchoreaassociated withHuntington's diseaseandtardive dyskinesia;and Ajovy (fremanezumab), used for the preventive treatment of migraine in adults. Additional branded drugs sold by Teva include Copaxone, Bendeka and Treanda, all of which are primarily sold in the United States.

Teva is listed on theTel Aviv Stock Exchangeand theNew York Stock Exchange.Its manufacturing facilities are located in Israel, North America, Europe, Australia, and South America. The company is a member of thePharmaceutical Research and Manufacturers of America(PhRMA).[4][5]

Teva Pharmaceuticals is the largest generic drug manufacturer in the world. Overall, Teva is the 18th largest pharmaceutical company in the world.[6]Teva has a history of legal trouble in relation to collusion and price-fi xing to inflate prices for drugs.[7]In 2023, Teva paid the largest fine to date for a domestic antitrust cartel in relation to a criminal investigation by the US Department of Justice into the company's price-fi xing.[8][9]

History

[edit]
Workers at Assia plant in the 1930s
Teva plant,Har Hotzvim,Jerusalem
Teva in Markham, Ontario

Salomon, Levin, and Elstein

[edit]

Teva's earliest predecessor was SLE, Ltd., a wholesale drug business founded in 1901 inOttoman Empire'sMutasarrifate of Jerusalem.SLE Ltd. took its name from the initials of its three cofounders: Chaim Salomon, Moshe Levin and Yitschak Elstein, and usedcamelsto make deliveries.[10]During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva and Zori. In the 1930s, Salomon, Levin, and Elstein Ltd. also founded Assia, a pharmaceutical company.[11]

Teva Pharmaceutical Industries

[edit]

1935–1949

[edit]

Teva Pharmaceutical Industries took its present form through the efforts ofGünther Friedländerand his aunt Else Kober on May 1, 1935. The original registration was under the nameTeva Middle East Pharmaceutical & Chemical Works Co. Ltd.in Jerusalem, then part ofMandatory Palestine.Friedländer was a German pharmacist, botanist and pharmacognosist, who immigrated to Mandatory Palestine in 1934.

The company was built with an investment of£4,900, which came from the family's owncapitaland partly from loans from other German immigrants. Capital shortage led to the joining of the bankerAlfred Feuchtwangeras a partner in Teva, who received 33% of the shares in return for his investment.[12]

Friedländer's business philosophy opined that the pharmaceutical industry has a reliable basis in difficult economic times, since "A Jewish mother will always buy medicine for her children". In theSecond World War,the company provided medicine to the allied forces and in particular to theBritish armypresent in theMiddle East.After the war, SirAlan Gordon Cunningham,the last of theHigh Commissioners for Palestine and Transjordan,visited Teva on behalf of theSecretary of State for the Colonies.His visit promoted Teva's reputation in the pharmaceutical market and created a momentum for Teva's development.

DuringMandatory Palestine,Teva exported its medical products to Arab countries. In 1941, Friedländer presented Teva products in anexhibitionheld inCairo,Egypt.The exhibition was sponsored by the General Agent and Sole Distribution ofmedicineinEgyptandSudan,SyriaandLebanon.Later on, Teva exported its products to theUS,Soviet Union(USSR), health institutes inDenmark,Czechoslovakia,PersiaandBurma.

1950–1999

[edit]

In 1951, Feuchtwanger initiated aninitial public offeringto raise capital through the newly foundedTel-Aviv Stock Exchangeand Teva became apublic company.[10]In 1954, Teva received a Certificate Excellence in Training award from the Israeli President,Yitzhak Ben Zvi.[citation needed]In 1964, Teva partnered with Sintex, a company from Mexico, andSchering Plough.[citation needed]

In 1964, Assia and Zori merged and in 1968 acquired a controlling stake in Teva.[13]In 1976, the three companies merged into the modern-day Teva Pharmaceutical Industries Ltd.[13]In 1980, Teva acquired Ikapharm, then Israel's second largest drug manufacturer.[14]

In 1980, Teva acquiredPlantex.[11]

In 1982, Teva was granted approval by theU.S. Food and Drug Administration(FDA) for itsKfar Sabamanufacturing plant.[15]

In 1995, Teva acquiredBiogal Gyógyszergyár Rt.(Debrecen,Hungary) and acquired ICI (Italy).[16]

2000s

[edit]

In 2000, Teva acquired Canada-basedNovopharm.[17]

In October 2003, Teva announced its intentions to acquire Sicor Inc. for $3.4 billion.[18]Following the announcement, the acquisition was completed on January 22, 2004, which marked Teva's entry intobiosimilars'market.[19]

In 2005, Teva opened a new, state-of-the-art pharmaceutical manufacturing plant inHar Hotzvim,a technology park inJerusalem.The plant received FDA approval in early 2007.[20]Teva entered the Japanese market in 2005 and in 2008 established a genericsjoint venturewithKowa.[21][22]

In January 2006, Teva acquired its U.S. rivalIvax Corporationfor $7.4 billion.[23][24]In 2008, sales totalled $11.08 billion, $13.9 billion in 2009, and in 2010 total sales rose to $16.1 billion, of which a major portion was in Europe and North America. On December 23, 2008, Teva acquiredBarr Pharmaceuticalsfor $7.5 billion, making Barr andPliva(which Barr bought earlier) part of Teva.[25]

2010s

[edit]

On March 18, 2010, Teva said it planned to acquire German genericRatiopharmfor US$5 billion. The deal was completed in August 2010, significantly expanding Teva's European coverage.[20][26][27][28]In May 2011, Teva boughtCephalonfor US$6.8 billion.[29]The same month, Teva announced the ¥40 billion purchase of a majority stake in Japanese generic drug companyTaiyo Pharmaceutical Industry,a move to secure a Japan-local production facility.[21]Teva completed the $934 million acquisition in July 2011.[30]In June 2013, Teva acquired US firm MicroDose Therapeutx for $40 million with as much as $125 million being paid in regulatory and developmental milestones[31]In 2010, Teva announced that it would build its main distribution center for the Americas in Philadelphia, PA, and was considering opening its US headquarters in the area.[20]In 2010, it had 39,660 employees. In Israel, the number of workers rose 7.5% by 6,774.[32]In October 2010, Teva entered a licensing agreement withBioTimeto develop and market BioTime's OpRegen for the treatment ofage-related macular degeneration,[33]an effort that in 2013 received $1.5 billion in funding from Israel'sOffice of the Chief Scientist.[34]

In May 2011, Teva announced it would purchaseCephalonfor US$6.8 billion.[35]

In January 2014, Teva acquiredNuPathe,after outbiddingEndo,for $144 million.[36]In June 2014, Teva acquiredLabrys Biologicsfor up to $825 million,[37]the aim being to strengthen the company's migraine pipeline through addition of LBR-101, an anti-CGRPmonoclonal antibody therapeutic.[38]

In March 2015, Teva acquiredAuspex Pharmaceuticalsfor $3.5 billion growing its CNS portfolio.[39]In April, Teva offered to acquireMylanfor $40 billion,[40]only a fortnight after Mylan offered to buyPerrigofor $29 billion.[41]Teva's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo.[42]Mylan stated in June 2015 that Teva's disclosure that it had a 1.35 percent stake in Mylan violatedUSantitrust rules.[43]In October, the company acquired Mexico-based Representaciones e Investigaciones Medicas (Rimsa) for around $2.3 billion.[44]In the same month Teva acquiredGecko Health Innovations.[45]In November 2015, the company announced it would collaborate withHeptares Therapeuticswith its work on small-moleculecalcitoningene-related peptideantagonistsfor migraine treatment, with the deal generating up to $410 million.[46]

Teva Active Pharmaceutical Ingredients (TAPI)operates within Teva as a stand-alone business unit. In 2009, TAPI's sales to third parties totaled $565 million, and in 2010 sales rose by 13% to a total of $641 million.[citation needed]

In July 2017, it was reported thatPascal Soriot,CEO ofAstraZenecasince 2012, would become the next CEO of Teva, succeeding Erez Vigodman,[47][48]however this was soon refuted.[49]As of August 2017, the company has struggled to attract a new CEO, leading to mounting questions for the board.[50]In August 2017, the board of directors announced a 75% cut in the dividend, reflecting declining profitability, and the share price fell by almost half in the days following.[51][52]As of September 11, 2017, Teva remained the “world's biggest seller of generics medicines.” On September 11, 2017, it was reported that they had selectedKåre Schultzas the new Teva CEO.[53]A day later the company announced it would sell itsParagardcontraceptive brand toCooper Cosfor $1.1 billion, with the funds being used to pay down debt.[54]Days later the company announced further divestments: a sale of contraception, fertility, menopause and osteoporosis products toCVC Capital Partners Fund VIfor $703 million and its emergency contraception brands for $675 million toFoundation Consumer Healthcare.[55]By December, the company had announced a drastic 25 percent workforce reduction (greater than 14,000 employees) as part of a two-year cost-reduction strategy.[56]Following considerable lobbying by the Israeli Government, from whom Teva received considerable tax breaks,[57]and from Israel's labor federation, the Histadrut, Teva agreed to delay some of the layoffs in Israel.[58]

In October 2019, Teva faced criticism for making a “business decision to discontinue the drug”Vincristine,essential for the treatment of most childhood cancers according to the Food and Drug Administration.[59][60]

Actavis Generics
[edit]
Main article:Actavis

In July 2015,Allerganagreed to sell itsgeneric drugbusiness (Actavis Generics[61]) to Teva for $40.5 billion[62][63][64]($33.75 billion in cash and $6.75 billion worth of shares).[65]As a result, Teva dropped its pursuit ofMylan.In order for the deal to gain regulatory approval, Teva sold off a number of assets, including a portfolio of five generic drugs to Sagent Pharmaceuticals for $40 million, as well as a further eight medicines toDr. Reddy'sin a $350 million deal.[61]Teva also sold a further 15 marketed generics, as well as three others that were close to market, for $586 million toImpax Laboratories.[66][67]In July, Teva sold off a further 42 products to Australian generics company,Mayne Pharma,for $652 million; the deal moved Mayne up 50 spots, into the top-25 companies of US generic companies.[68]As part of the deal Teva will seek to raise $20 to $25 billion[69]through a bond sale.[70]

After completing the $39 billion acquisition of Actavis Generics, Teva announced another, smaller, deal with Allergan, agreeing to acquire its generic distribution businessAndafor $500 million.[71]

2010s divestments
[edit]

On October 21, 2011, Par Pharmaceutical has sealed the deal to three products from Teva Pharmaceutical Industries, which the Israeli firm was required by the US Federal Trade Commission to divest before it could acquire US biotech Cephalon for $6.8 billion.[72]

Following the acquisition of Allergan plc generic division some assets have been sold off to meet US antitrust requirements.[73]In June 2016 Indian pharmaceutical company Dr. Reddy's Laboratories Ltd bought 8 (ANDA)Abbreviated New Drug Applicationsfor $350 million in cash.[74]Also in June 2016 Teva sold two ANDAs to Indian pharmaceutical company Zydus Cadilla, strengthening its US portfolio.[75]On June 21, 2016, American pharmaceutical company Amneal Pharmaceutical previously known as Impax Laboratories bought a portfolio of generic drugs from Teva Pharmaceutical Industries for about $586 million.[76]On July 29, Cipla an Indian pharmaceutical company bought three products from Teva.[77]Indian pharmaceutical company, Aurobindo, was in the race to buy some Teva assets. In October 2016, Teva has sold off part of its UK and Ireland generic business to Indian pharmaceutical company Intas Pharma for 600 million pounds (5083 crore Indian rupees) in cash.[78]In August 2016, Australia pharmaceutical company Mayne Pharmaceutical bought a portfolio of drugs from pharmaceutical giant Teva Pharmaceuticals last year for $845 million Australian dollars.[79]In February 2018, Teva Pharmaceutical Industries Ltd has completed the sale of a portfolio of products within its global women's health business across contraception, fertility, menopause and osteoporosis for $703 million in cash to CVC Capital Partners Fund VI.[80]Teva also agreed to sell its Plan B One-Step and its brands of emergency contraception to Foundation Consumer Healthcare for $675 million in cash. Combined annual net sales of these products were $140 million last year.[81]It also sold Paragard to a unit of Cooper Companies Inc (COO.N) for $1.1 billion.[81]

Acquisition history

[edit]

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Teva Pharmaceutical Industries

Gecko Health Innovations
(Acq 2015)

Rimsa
(Acq 2015)

Actavis Generics
(Generic drug divAllergan, plc,Acq 2015)

Auspex Pharmaceuticals
(Acq 2014)

Labrys Biologics
(Acq 2014)

NuPathe after
(Acq 2014)

MicroDose
(Acq 2013)

Taiyo Pharmaceutical Industry
(Acq 2011)

Cephalon
(Acq 2011)

Arana Therapeutics
(Acq 2009)

ChemGenex Pharmaceuticals
(Acq 2011)

Ratiopharm
(Acq 2010)

Barr Pharmaceuticals
(Acq 2008)

IVAX Corporation
(Acq 2006)

Novopharm
(Acq 2000)

Plantex
(Acq 1980)

Ikapharm
(Acq 1980)

Salomon, Levin, and Elstein Ltd
(Merged 1976 to form Teva Pharmaceutical Industries Ltd)

Assia
(Merged 1976 to form Teva Pharmaceutical Industries Ltd)

Zori
(Merged 1976 to form Teva Pharmaceutical Industries Ltd)

Glaxo
(Acq 1914)

Margarine Unie
(Acq 1924)

Allen & Hanburys
(Merged 1976 to form Teva Pharmaceutical Industries Ltd)

Corporate governance

[edit]
Chief Executive Officer Period of office Notes
Eli Hurvitz 1976 to 2002 CEO & Chairman of the board until his death in 2011.[82][83]
Israel Makov 2002 to 2007 [84][85]
Shlomo Yanai March 2007 to May 2012 Announced his resignation at the beginning of 2012.[86]
Jeremy Levin May 2012 to October 2013 [87]
Eyal Desheh October 2013 to January 2014 Interim CEO
Erez Vigodman January 2014 to February 2017 Desheh returned to previous position ofchief financial officer.[88][89][90]Vigodman served as the CEO ofMakhteshim Aganuntil joining Teva, and was president and CEO ofStrauss Groupprior to this.[90]From 2014,Michael Haydenserved as Teva'schief scientific officerand president of the company's global research and development.[38]
Yitzhak Peterburg February 2017 to Sept 2017 Peterburg held the position of chairman since 2015. He was appointed as interim president and CEO in 2017 succeeding Erez Vigodman. Since Israeli law does not permit the same individual to serve as CEO and chairman, Sol J Barer took over as the chairman of the board in February 2017.[91]
Kåre Schultz[53] September 2017 – 2022 Schultz was appointed as the CEO and president succeeding the acting president and CEO Yitzhak Peterburg.[92][93]
Richard Francis January 2023 – present [3]

Research and development

[edit]
Copaxone,a Teva patented drug

Teva holds patents on multiple drugs, includingCopaxone,a specialty drug[94](for the treatment ofmultiple sclerosis), now the world's best selling MS drug,[9]andAzilect(sold as Agilect in some countries) for treatment ofParkinson's disease.By July 2015, Copaxone held a "31.2 percent shares of total MS prescriptions in the United States."[9]Teva's new 40 mg version of Copaxone taken three times a week "accounted for 68.5 percent of total Copaxone prescriptions in the United States."[9]Copaxone accounts for about fifty percent of "Teva's profit and 20 percent of revenue."[9]Competitors' Glatopa, 20 mg version of Copaxone, is taken once a day.[9]

In June 2006, Teva received from the FDA a 180-day exclusivity period to sellsimvastatin(Zocor) in the U.S. as ageneric drugin all strengths except 80 mg. Teva presently[when?]competes with the maker of brand-name Zocor,Merck & Co.;Ranbaxy Laboratories,which has 180-day exclusivity for the 80 mg strength; andDr. Reddy's Laboratories,whose authorized generic version (licensed by Merck) is exempt from exclusivity.

In June 2010, the company announced it would discontinue its production ofpropofol,a major sedative estimated to be used in 75% of all US anesthetic procedures.[95]

In March 2015, Teva sold four anti-cancer compounds toIgnyta Inc.for $41.6 million. As part of the deal Teva sold the following compounds which were then renamed:[96]

  • CEP-32496 (renamed RXDX-105) a small molecule inhibitor ofBRAF,EGFRandRET,now in Phase I/II trials
  • CEP-40783 (renamed RXDX-106) a small molecule inhibitor ofAXLandc-Metin preclinical development
  • CEP-40125 (renamed RXDX-107) a nanoformulation of a modifiedbendamustinewith potential activity in solid tumours. Bendamustine Rapid Infusion as therapy for CLL and NHL is part of Teva'sspecialty drugspipeline.[94]
  • TEV-44229 (renamed RXDX-108) a potent inhibitor of thekinasePKCiota

In July 2019, the company stopped production ofVincristine,a critical drug used to treat the most common forms of childhood cancer, and was criticized by media for creating a worldwide shortage of the drug.[97]On 28 January 2020, the company announced that theFood and Drug Administration (FDA)had approved an autoinjector device for Ajovy (fremanezumab-vfrm) injection.[98]

[edit]

On June 25, 2010,Bayersued Teva for falsely claiming that Teva's Gianvi was stabilized by betadex as aclathrate,and could consequently be advertised as a generic ofYaz[99][100]The settlement resulted in Teva changing its product marketing to remove the claim that it used the same ingredients as Yaz.[101]Bayer's method specifically prevents oxidative degradation of the estrogen, while Teva's does not.

In January 2015, theSupreme Court of the United Statesdecided for Teva on theCopaxonepatent inTeva Pharmaceuticals USA, Inc. v. Sandoz, Inc.[102]

In December 2016, theattorneys generalof 20 states filed a civil complaint accusing Teva of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint allegedprice collusion schemesbetween six pharmaceutical firms including informal gatherings, telephone calls, and text messages.[103]

In January 2019, the Supreme Court of the United States decided for Teva inHelsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc.[104]

On May 11, 2019, Teva Pharmaceuticals USA was one of 19 drug companies sued for price fi xing in the United States by 44 states for inflating its prices, sometimes up to 1000%, in an illegal agreement among it and its competitors.[7]In June 2021, Teva agreed to pay $925M to settle allegations it had engaged in price fi xing inMississippi.[105]In January 2022, Teva agreed to pay $425M to settle allegations that it had concealed price fi xing practices from shareholders.[106]

In May 2019, Teva Pharmaceuticals USA agreed to pay $85 million to the U.S. state of Oklahoma to settle allegations that it had been overprescribing opioids, marketing them as safe, and downplaying their addictive qualities.[107]

In July 2019, Teva paid $69 million to settlepay-for-delayclaims.[108]

In 2021, New York Attorney GeneralLetitia Jamesfiled a lawsuit against Teva and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York.[109]

In February 2022, Teva agreed to a $225 million settlement with the state of Texas to end claims that it fueled an opioid epidemic in the state by improperly marketing pain medicine.[110]

In August 2023, Teva admitted to price-fi xing charges related to the generic cholesterol drugPravastatin,and agreed to pay a $225 million fine, after a criminal investigation by the US Department of Justice.[8]The US Department of Justice stated that the settlement was "the largest to date for a domestic antitrust cartel."[111]

Also in August 2023, Teva agreed to a legal settlement with US hospitals over its marketing ofopioidproducts that ultimately raised costs for health providers and contributed to theOpioid epidemic in the United States.[112]The lawsuit consisted of roughly 500 hospitals and health providers, resulting in a payment from Teva of $126 million over 18 years.

Pharmaceutical products

[edit]

A full list of products destined for the US market is available fromtevagenerics.Teva also manufactures generic medications for use outside of the US;Cyproterone acetate[113]andMoclobemide[114]being two examples.

Recalls

[edit]

In 2018-2019, Teva Pharmaceuticals USA recalledantihypertensivetablets containingvalsartanandlosartandue to the detection beyond acceptable limit ofN-nitrosodiethylamine(NDEA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA), respectively, which are probable human carcinogens.[118][119]

See also

[edit]

References

[edit]
  1. ^"TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Israel Company Reports – Search Israeli Companies".israelbizreg.RetrievedOctober 19,2016.
  2. ^abcdef"2023 Annual Report (Form 10-K)".US Securities and Exchange Commission. February 12, 2024.
  3. ^Kiliç, Burcu (July 31, 2014).Boosting Pharmaceutical Innovation in the Post-TRIPS Era.Edward Elgar Publishing.ISBN9781782544135.RetrievedMay 23,2017– via Google Books.
  4. ^"Teva wins controversial PhRMA bid despite protests from branded rivals – FiercePharma".fiercepharma.July 18, 2016.RetrievedMay 23,2017.
  5. ^"Teva, one of the biggest generic makers, joins the brand-name club".STAT.July 18, 2016.RetrievedAugust 20,2017.
  6. ^"The top 20 pharma companies by 2020 revenue".FiercePharma.March 29, 2021.RetrievedJune 15,2021.
  7. ^ab"Drugmakers allegedly inflated prices over 1,000% and 44 states are now suing".CNBC.May 11, 2019.RetrievedMay 12,2019.
  8. ^abMaruf, Ramishah (August 21, 2023)."Teva to pay $225 million fine and divest cholesterol drug to settle price-fi xing charges | CNN Business".CNN.RetrievedAugust 24,2023.
  9. ^abcdef"Teva's MS drug Copaxone has strong second-quarter sales".Reuters.Jerusalem, Israel. July 2015.RetrievedOctober 16,2015.
  10. ^abKiliç, Burcu (July 31, 2014).Boosting Pharmaceutical Innovation in the Post-TRIPS Era.Edward Elgar Publishing.ISBN9781782544135.RetrievedMay 23,2017– via Google Books.
  11. ^ab"Teva — Plantex Limited".tapi.Archived fromthe originalon November 8, 2014.RetrievedNovember 7,2014.
  12. ^Specht, Heike (October 24, 2013).Die Feuchtwangers: Familie, Tradition und jüdisches Selbstverständnis.Wallstein Verlag.ISBN9783835306639.RetrievedFebruary 21,2019– via Google Books.
  13. ^abBenari, Elad (November 22, 2011)."Former CEO of Teva Pharmaceuticals Dies at 79 - Inside Israel".Israel National News.RetrievedApril 21,2020.
  14. ^"Teva > the History of Teva".Archived fromthe originalon March 17, 2007.RetrievedMarch 17,2007.The History of Teva
  15. ^Odagiri, Hiroyuki; Goto, Akira; Sunami, Atsushi; Nelson, Richard R. (April 8, 2010).Intellectual Property Rights, Development, and Catch Up: An International Comparative Study.OUP Oxford. p. 234.ISBN978-0-19-957475-9.
  16. ^"Improving health since 1901".tevapharm.
  17. ^"TEVA NOVOPHARM — Novopharm Limited becomes Teva Canada Limited".newswire.ca.Archived fromthe originalon November 7, 2014.RetrievedNovember 7,2014.
  18. ^Jerry Hirsch (November 1, 2003)."Drug Maker Teva to Buy Sicor".Los Angeles Times.
  19. ^"Teva Completes Acquisition of Sicor".January 22, 2004. Archived fromthe originalon January 7, 2018.RetrievedJanuary 6,2018.
  20. ^abcSinger, Natasha (March 18, 2010)."Teva to Acquire Top German Generics Maker for $5 Billion".The New York Times.RetrievedMarch 18,2010.
  21. ^abGrogan, Kevin (May 5, 2011)."Teva plans $500 million Japan acquisition".PharmaTimes Magazine.London, England. Online PharmaTimes. Archived fromthe originalon May 10, 2011.RetrievedMay 7,2011.
  22. ^"Kowa, Teva to form generic drug venture".The Japan Times Online.September 25, 2008.RetrievedAugust 20,2017.
  23. ^Jennifer Bayot for the New York Times. July 26, 2005Teva to Acquire Ivax, Another Maker of Generic Drugs
  24. ^Teva Press Release, 2006.Teva Completes Acquisition of Ivax
  25. ^"Teva Completes Acquisition of Barr".tevapharm.Archived fromthe originalon January 24, 2009.
  26. ^"Pharmaceutical and Pellets manufacturing company | Ravoos".ravoos.
  27. ^Jonathan D. Rockoff; Eyk Henning (March 19, 2010)."Teva to Acquire Generics Firm".The Wall Street Journal.New York City. WSJ. Archived fromthe original(~100 words)on June 4, 2011.RetrievedMay 8,2011.
  28. ^Robert Daniel; Polya Lesova (March 18, 2010)."Teva to acquire Ratiopharm in deal valued near $5 billion".MarketWatch.New York City:Dow Jones & Co.Archived fromthe originalon March 23, 2010.RetrievedMay 8,2011.
  29. ^Nicholson, Chris V. (May 2, 2011)."Teva to Buy Cephalon for $6.8 Billion".The New York Times.
  30. ^"Teva completes $934m Taiyo acquisition".Globes.co.il.July 14, 2011.
  31. ^Wainer, David (June 17, 2013)."Teva Adds MicroDose to Respiratory Business in $165 Million Deal".Bloomberg.
  32. ^Yeshayahou, Koby (February 16, 2011)."Teva employees gain $222m on options".Globes.Rishon Le-Zion, Israel:Globes Publisher Itonut.globes-online. Archived fromthe originalon February 17, 2011.
  33. ^"Cell Cure Neurosciences Ltd., a Subsidiary of BioTime, Inc. and Hadasit Bio Holdings Ltd., Enters into an Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd".businesswire.October 11, 2010.
  34. ^"BioTime's Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel's Office of the Chief Scientist".businesswire.May 13, 2013.
  35. ^Nicholson, Chris V. (May 2, 2011)."Teva to Buy Cephalon for $6.8 Billion".The New York Times.RetrievedApril 21,2020.
  36. ^"Teva Outbids Endo, Acquires NuPathe for $144M+". News: Industry Watch.Gen. Eng. Biotechnol. News(paper). Vol. 34, no. 4. February 15, 2014. p. 10.
  37. ^Staff (June 3, 2014)."Teva Buys Labrys, Growing Pain Franchise in Up to $825M Deal".Genetic Engineering & Biotechnology News.RetrievedJuly 21,2014.
  38. ^abGeorge, John (July 21, 2014)."Teva completes deal for second migraine-treatment developer".Philadelphia Business Journal.RetrievedJuly 21,2014.
  39. ^Staff (March 30, 2015)."Teva to Acquire Auspex for $3.5B, Growing CNS Portfolio".GEN News Highlights.Genetic Engineering & Biotechnology News.RetrievedApril 21,2015.
  40. ^Staff (April 21, 2015)."Teva Offers to Buy Mylan for $40B".GEN News Highlights.Genetic Engineering & Biotechnology News.RetrievedApril 21,2015.
  41. ^Staff (April 8, 2015)."Mylan Offers $28.9B for Perrigo".GEN News Highlights.Genetic Engineering & Biotechnology News.RetrievedApril 21,2015.
  42. ^"Teva Offers to Buy Mylan in $40.1B Cash-And-Stock Deal".Pharmaceutical Processing.Associated Press. April 21, 2015.RetrievedApril 21,2015.
  43. ^Rao Koppala, Anjali (June 1, 2015)."Mylan says Teva's stake buy violates U.S. antitrust rules".Reuters.RetrievedJune 2,2015.
  44. ^"Teva beefs up in emerging markets with $2.3B Rimsa buyout".FiercePharma.October 2015.
  45. ^"Teva snaps up Gecko and its 'smart inhaler' to pump up respiratory meds".FiercePharma.
  46. ^"Teva, Heptares Launch Up-to-$410M+ Migraine Alliance".GEN Eng News.November 25, 2015.
  47. ^"AstraZeneca's CEO Soriot to join Israeli drugs company Teva: report".Reuters. May 14, 2014.RetrievedJuly 12,2017.
  48. ^"Israeli newspaper reports that AstraZeneca CEO Pascal Soriot has agreed to take the helm at Teva – ENDPOINTS NEWS".Endpts.RetrievedJuly 12,2017.
  49. ^Boland, Hannah (July 14, 2017)."Pascal Soriot looks set to stay as AstraZeneca chief".The Daily Telegraph.Archivedfrom the original on January 12, 2022.RetrievedMay 15,2018.
  50. ^Jones, Rory (August 7, 2017)."Teva Pharmaceutical Industries faces high price for new chief".The Wall Street Journal.RetrievedAugust 6,2017.
  51. ^"Teva Reports Second Quarter 2017 Financial Results".corporate-ir.net(Press release). Teva. August 3, 2017. Archived fromthe originalon August 24, 2019.RetrievedAugust 8,2017.
  52. ^"Teva stock price chart".Google Finance.RetrievedAugust 8,2017.
  53. ^abJones, Rory (September 11, 2017)."Teva Appoints New Chief Executive After Months of Speculation".Wall Street Journal.New York City, New York.RetrievedSeptember 11,2017.
  54. ^"Teva to sell contraceptive brand Paragard in $1.1 billion deal".Reuters. September 11, 2017. Archived fromthe originalon February 21, 2019.RetrievedFebruary 21,2019.
  55. ^"Teva finishes women's health sale with deals worth $1.38B".fiercepharma.September 18, 2017.RetrievedFebruary 21,2019.
  56. ^Barber, Joe (December 14, 2017)."Teva to cut over 25 percent of global workforce".First Word Pharma Plus.Doctor's Guide Publishing Limited.RetrievedFebruary 9,2018.
  57. ^Schindler, Max (December 22, 2017)."Economy Minister: Teva Should Earn Its Tax Breaks".Jerusalem Post.
  58. ^Weinreb, Gali (January 1, 2018)."Teva Dewlays 33% of Jerusalem Layoffs Until 2019".Jerusalem Post.
  59. ^The New York Times, "Faced with a Drug Shortfall, Doctors Scramble to Treat Children with Cancer," Oct 28, 2019[1]
  60. ^ABC News, "Shortage of critical cancer drug forcing some children to go without," Oct 22, 2019[2]
  61. ^ab"Analyst cuts Allergan generics sales estimates as Teva deal close nears".FiercePharma.June 16, 2016.
  62. ^"Teva to Buy Allergan's Generic Drug Unit".Bloomberg.July 27, 2015.
  63. ^Cynthia Koons (July 27, 2015)."Teva CEO: $40.5 Billion Allergan Deal is Just the Beginning - Bloomberg Business".Bloomberg.
  64. ^"Teva Purchasing Allergan's Generics Unit in $40.5B Deal".Bloomberg.July 27, 2015.
  65. ^Somayaji, Chitra (July 27, 2015)."Teva Snaps Up Allergan's Generics Arm, Dumping Mylan".Bloomberg.
  66. ^"Impax Buys Generic Product Portfolio from Teva, Allergan for $586M".GEN Genetic Engineering & Biotechnology News.Mary Ann Liebert, Inc. June 21, 2016.
  67. ^"Teva sells castoffs to Impax for $586M as clock ticks on Allergan deal".FiercePhama.June 21, 2016.
  68. ^"Mayne vaults ahead in U.S. with $652M deal for Teva/Allergan meds".FiercePharma.June 28, 2016.
  69. ^"Teva looks for $20B-plus from bond sale to finance Allergan deal".FiercePharma.July 14, 2016.
  70. ^"Form 6-K".SEC.gov.Securities & Exchange Commission.
  71. ^"After Completing $39B Acquisition, Teva Does Another Generics Deal with Allergan".GEN Genetic Engineering & Biotechnology News.Mary Ann Liebert, Inc. August 3, 2016.RetrievedMay 23,2017.
  72. ^"Par acquires Teva's divested ANDAs, and is already shipping fentanyl citrate".Scrip.October 21, 2011.RetrievedMay 27,2019.
  73. ^"Teva Completes Acquisition of Actavis Generics".tevapharm.RetrievedMay 27,2019.
  74. ^"India's Dr Reddy's in $350 million deal to buy eight U.S. drugs..."Reuters.June 11, 2016.RetrievedMay 27,2019– via reuters.
  75. ^"Zydus Cadila acquires two drugs from Teva to strengthen US portfolio".VCCircle.June 20, 2016.RetrievedMay 27,2019.
  76. ^"Impax Buys Generic Drugs from Teva and Allergan for $586 Million".Fortune.RetrievedMay 27,2019.
  77. ^"Cipla, Aurobindo Pharma to acquire drugs from Teva".VCCircle.July 29, 2016.RetrievedMay 27,2019.
  78. ^Balakrishnan, Swaraj Singh Dhanjal, Reghu (October 5, 2016)."Intas Pharma to buy Teva's UK, Ireland generics businesses".Mint.RetrievedMay 27,2019.{{cite web}}:CS1 maint: multiple names: authors list (link)
  79. ^"Mayne Pharma profit soars on Teva deal".Australian Financial Review.February 23, 2017.RetrievedMay 27,2019.
  80. ^"Teva Announces Completion of Global Women's Health Divestiture to CVC Capital Partners".businesswire.February 1, 2018.RetrievedMay 27,2019.
  81. ^ab"Teva Pharma to sell more women's health assets for $1.38 billion".Reuters.September 18, 2017.RetrievedMay 27,2019– via reuters.
  82. ^"Teva Pharmaceutical Industries Ltd (TEVA.O) Officers".Reuters. Archived fromthe originalon September 29, 2008.RetrievedOctober 11,2008.
  83. ^Coren, Ora (February 21, 2008)."Most respected managers in market: Tshuva, Dankner, Maor and Hurvitz".Haaretz.Archived fromthe originalon October 20, 2012.RetrievedMarch 21,2014.
  84. ^ Teva Pharmaceuticals Inc. (February 14, 2002)."Teva news release hiring Israel Makov".RetrievedSeptember 28,2014.
  85. ^ Golan Hazani. (October 18, 2006)."Ynet reports Israel Makov resignation".Ynetnews.RetrievedSeptember 28,2014.
  86. ^ "Teva CEO Shlomo Yanai leaving in May, to be replaced by American".Haaretz.RetrievedDecember 7,2013.
  87. ^ "Teva CEO Jeremy Levin steps down".Globes.Archived fromthe originalon November 4, 2013.RetrievedOctober 30,2013.
  88. ^"Teva Names a New Chief Executive".Business Day.The New York Times.Bloomberg News. January 2, 2012. Archived fromthe originalon April 27, 2012.RetrievedJanuary 3,2012.(registration required)
  89. ^"Israel's Teva Pharm names Vigodman as CEO".Reuters.January 9, 2014.Archivedfrom the original on January 9, 2014.
  90. ^ab"People".Gen. Eng. Biotechnol. News(paper). Vol. 34, no. 4. February 15, 2014. p. 41.
  91. ^"Sign In".sso.tevapharm.
  92. ^Jones, Rory (September 11, 2017)."Teva Appoints New Chief Executive After Months of Speculation".Wall Street Journal.ISSN0099-9660.RetrievedSeptember 12,2017.
  93. ^Scheer, Steven; Jacobsen, Stine (September 11, 2017)."Drugmaker Teva hires Lundbeck CEO Schultz to restore its health".Reuters.RetrievedSeptember 12,2017.
  94. ^ab"Our Specialty Pipeline".Teva Pharmaceutical Industries.nd.RetrievedOctober 16,2015.
  95. ^"Teva won't make more of powerful sedative".NBC News.May 28, 2010.
  96. ^"GEN — News Highlights:Ignyta Buys Four Cancer Compounds from Teva".GEN.March 18, 2015.
  97. ^Rabin, Roni Caryn (October 14, 2019)."Faced With a Drug Shortfall, Doctors Scramble to Treat Children With Cancer".The New York Times.
  98. ^"Teva Announces FDA Approval of AJOVY® (fremanezumab-vfrm) Injection Autoinjector".tevapharm.RetrievedFebruary 14,2020.
  99. ^ Bayer HealthCare Pharmaceuticals Inc. (June 25, 2010)."Bayer Sues Teva and Barr for False Advertising and Patent Infringement in Connection with Teva's Generic Oral Contraceptive Gianvi".Archived fromthe originalon January 3, 2011.RetrievedDecember 26,2010.
  100. ^ Backensfeld; et al. (August 25, 1998)."Solid dosage forms that contain clathrates of 17. Alpha.-ethinyl estradiol".Archived fromthe originalon December 20, 2016.RetrievedDecember 26,2010.
  101. ^Maureen M Cavanaugh, Teva Pharmaceuticals (July 1, 2010)."Microsoft Word – Gianvi Pharmacist Letter – RevD – Final 7-1-10 – web versi..."(PDF).Archived fromthe original(PDF)on March 14, 2012.RetrievedDecember 26,2010.
  102. ^"Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc".SCOTUSblog.RetrievedJanuary 27,2015.
  103. ^Thomas, Katie (December 15, 2016)."20 States Accuse Generic Drug Companies of Price Fi xing".The New York Times.RetrievedDecember 16,2016.
  104. ^"Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc".SCOTUSblog.RetrievedFebruary 21,2019.
  105. ^"Teva reaches $925K settlement with Mississippi in price-fi xing case—and it hopes other states will follow suit".FiercePharma.June 23, 2021.RetrievedFebruary 22,2022.
  106. ^"Teva ponies up $420M to settle with investors who said company hid price-fi xing scheme".FiercePharma.January 19, 2022.RetrievedFebruary 22,2022.
  107. ^"Johnson & Johnson in billion-dollar opioid trial".May 28, 2019.RetrievedMay 31,2019.
  108. ^"Three drugmakers settle with California over deals to keep generic medications off the market".Los Angeles Times.July 29, 2019.
  109. ^Nir, Sarah Maslin (June 29, 2021)."Major Trial Against Opioid Suppliers Begins in New York".The New York Times.ISSN0362-4331.RetrievedJuly 1,2021.
  110. ^"Teva Pharmaceuticals to Pay $225M to Texas to Settle Opioid Epidemic Claims".Top Class Actions.February 9, 2022.RetrievedFebruary 15,2022.
  111. ^"Office of Public Affairs | Major Generic Drug Companies to Pay Over Quarter of a Billion Dollars to Resolve Price-Fi xing Charges and Divest Key Drug at the Center of Their Conspiracy | United States Department of Justice".justice.gov.August 21, 2023.RetrievedAugust 24,2023.
  112. ^Pierson, Brendan (August 3, 2023)."Teva agrees to pay $126 million to US hospitals over opioids".Reuters.RetrievedSeptember 12,2023.
  113. ^(From Dutch subsidiary Teva Pharmachemie)"Cyproteronacetaat 50 PCH".College ter Beoordeling van Geneesmiddelen.
  114. ^"Moclobemide 150 Teva".College ter Beoordeling van Geneesmiddelen.
  115. ^Mfg. byWatson Pharmaceuticals.SeeActavis Acquisition and Watson Name Change,andAllergan, Inc. Acquisition and Actavis, plc Name Change
  116. ^DeNoon, D. (August 3, 2012). Generic singulair approved. Retrieved fromhttp:// webmd /asthma/news/20120803/generic-singulair-approved
  117. ^"Teva Announces Launch Of Generic Protonix Tablets".tevapharm.Archived fromthe originalon December 29, 2007.
  118. ^"Teva Pharmaceuticals USA Issues Voluntary Nationwide Recall of All Amlodipine/Valsartan Combination Tablets and Amlodipine/Valsartan/Hydrochlorothiazide Combination Tablets That Are Within Expiry".Food and Drug Administration.November 27, 2018. Archived fromthe originalon December 4, 2018.Teva Pharmaceuticals has initiated a voluntary recall in the United States, to the patient level, of all lots of Amlodipine / Valsartan combination tablets and Amlodipine / Valsartan / Hydrochlorothiazide combination tablets...due to an impurity detected above specification limits in an active pharmaceutical ingredient (API)...as N-nitroso-diethylamine (NDEA), which has been classified as a probable human carcinogen.
  119. ^"Teva Pharmaceuticals USA, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium 25 mg and 100 mg Tablets USP, Sold Exclusively to Golden State Medical Supply".Food and Drug Administration.April 29, 2019. Archived fromthe originalon May 5, 2019.Teva Pharmaceuticals USA, Inc. has initiated a voluntary recall in the United States, to the patient level...Losartan Potassium USP Tablets...This recall is due to the detection of an impurity – N-Nitroso-N-methyl-4-aminobutyric acid (NMBA)...that is above...interim acceptable exposure limit of 9.82 ppm. Based on the available information, the risk of developing cancer in a few patients following long-term use of the product cannot be ruled out.
[edit]
Wikimedia Commons has media related toTeva Pharmaceutical Industries.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Teva_Pharmaceuticals&oldid=1247951200"